Free Trial
OTCMKTS:MKKGY

Merck KGaA 5/15/2025 Earnings Report

Merck KGaA logo
$26.73 +0.51 (+1.95%)
As of 03:59 PM Eastern

Merck KGaA EPS Results

Actual EPS
$0.59
Consensus EPS
$0.50
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Merck KGaA Revenue Results

Actual Revenue
$5.89 billion
Expected Revenue
$5.32 billion
Beat/Miss
Beat by +$571.25 million
YoY Revenue Growth
N/A

Merck KGaA Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Merck KGaA's next earnings date is estimated for Thursday, August 7, 2025, based on past reporting schedules.

Conference Call Resources

Merck KGaA Earnings Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
The Motley Fool: Merck’s risks and potential
See More Merck KGaA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merck KGaA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck KGaA and other key companies, straight to your email.

About Merck KGaA

Merck KGaA (OTCMKTS:MKKGY), headquartered in Darmstadt, Germany, is a leading science and technology company with a heritage dating back to 1668. Over its more than three centuries of history, the company has evolved from a family-run apothecary into a global enterprise operating in the healthcare, life science and electronics sectors. Merck KGaA distinguishes itself by integrating chemistry, biotechnology and advanced materials to develop innovative solutions across a variety of industries.

In its Healthcare division, Merck KGaA focuses on prescription pharmaceuticals in areas such as oncology, immuno-oncology, neurology, fertility and endocrinology. The company’s portfolio includes targeted therapies, biologics and small-molecule drugs designed to address critical unmet medical needs. Through a robust pipeline and strategic collaborations, the division aims to advance novel treatments from early research to clinical application.

The Life Science arm serves academic research, biotech and pharmaceutical customers with an extensive range of products and services. These include lab reagents, cell culture media, instruments for analytical and preparative processes, and custom services for process development and manufacturing of biologics. By offering end-to-end solutions, Merck KGaA supports innovation throughout the drug discovery and production lifecycle.

Merck KGaA’s Electronics division supplies specialty materials for the semiconductor and display industries, including photoresists, high-purity chemicals and liquid crystals for flat-panel displays. With operations in over 60 countries, the company leverages its global footprint to meet regional market needs. Under the leadership of Chief Executive Officer Belén Garijo, Merck KGaA continues to invest in research and development, aiming to drive sustainable growth and address challenges in health, science and technology worldwide.

View Merck KGaA Profile

More Earnings Resources from MarketBeat